AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00071422
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mL, once daily, self-administered SC injection for 90 days
Trial: NCT00126789
Drug: Fentanyl Transdermal Matrix Patch ZR-02-01
RxNorm normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ZR-02-01 patch contains fentanyl dispersed in a solid matrix, and will be available in 25, 50, 75 and 100 mcg/hr patches. The patches will be worn on the chest or upper arm and an overlay will be placed over the patch. Patches (and overlays) will be replaced every 3 days by the patient and/or responsible caregiver. If a patient experiences end-of-dose-failure, the dosing interval may be changed by the physician investigator to every 2 days. The maximum dose allowed in this study is 300 mcg/hr.
Trial: NCT02488525
Drug: Prophylactic treatment with Wilfactin
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic treatment with Wilfactin after implantation of continuous-flow left ventricular assist device reduces the frequency of bleeding in comparison to the usual care.
Trial: NCT01707368
Drug: Daivobet® Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily on areas with plaque psoriasis, treatment duration up to 8 weeks for body skin areas except scalp (scalp up to 4 weeks), treatment may be repeated under medical surveillance.
Trial: NCT01947959
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For DVT/PE treatment and SPAF, standard of care is treatment with the most widely used vitamin K antagonist, phenprocoumon, and for the secondary prevention of ACS, standard of care is antiplatelet drug(s) such as low-dose acetylsalicylic acid, clopidogrel, dipyridamole, prasugrel, ticlopidine and ticagrelor.
Trial: NCT04233424
Drug: D-PLEX
RxNorm normalized name: Kleer Plex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-PLEX is a new formulation of extended release of Doxycycline. Each 5g D-PLEX vial contains 54.6mg Doxycycline free base (1.09%), which is equivalent to 63mg Doxycycline hyclate (1.26%). D-PLEX is supplied as a sterile powder to be reconstituted to paste in the operating room, using standard aseptic techniques and is intended for single administration. The non-active components of the extended release antibiotic formulation are β Tri-Calcium polymer and a lipid matrix. All formulation components are biodegradable.
Trial: NCT01721317
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be available
Trial: NCT01044108
Drug: '2-0453
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of multiple subcutaneous (under the skin) doses for 10 weeks. Up to 4 escalating dose levels will be investigated. Progression to next dose level will be based on a safety evaluation.
Trial: NCT01044108
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as a comparator at each dose level.
Trial: NCT00195455
Drug: 17b Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01778634
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin intravenous 20 mg/kg every 24 h x 3 days
Trial: NCT01778634
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D5W
Trial: NCT00999817
Drug: test [PF-00299804 + dextromethorphan]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single 45 mg oral dose of PF-00299804 and a single 30 mg oral dose of dextromethorphan
Trial: NCT00959218
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral solution
Trial: NCT01117649
Drug: HES 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HES 10% dissolved in plasma adapted Ringer's solution (balanced solution).
Trial: NCT01117649
Drug: HES 6%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HES 6% dissolved in plasma adapted Ringer's solution (balanced solution)
Trial: NCT01117649
Drug: balanced electrolyte solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: plasma adapted Ringer's solution
Trial: NCT00534456
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group to receive volume and dose frequency changes resembling titration dosing in the treatment group.
Trial: NCT03302208
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02258867
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for subcutaneous injection
Trial: NCT00444587
Drug: Second line chemotherapy
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As prescribed
Trial: NCT04407273
Drug: observational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: observational study
Trial: NCT04170465
Drug: AC-T chemotherapy regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AC: (Doxorubicin 60 mg/m2 IV + cyclophosphamide 600 mg/m2 IV) for 4 cycles every 3 weeks followed by Taxol cycles (Paclitaxel 80 mg/m2 IV) once weekly for 12 weeks.
Trial: NCT00720421
Drug: AZD7325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD7325 10 mg oral 2 capsules
Trial: NCT00720421
Drug: AZD7325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD7325 1 mg oral 2 capsules
Trial: NCT00720421
Drug: AZD7325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD7325 Placebo oral 2 capsules
Trial: NCT02670330
Drug: SD-101-6.0 cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-6.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 6% and other excipients.
Trial: NCT03359694
Drug: DT group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated liposomal doxorubicin 30mg/m2，iv，d1， Docetaxel 75mg/m2，iv，d1， q21d×6
Trial: NCT03359694
Drug: ET group
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional doxorubicin 75mg/m2，iv，d1， Docetaxel 75mg/m2，iv，d1， q21d×6
Trial: NCT03359694
Drug: NX group
RxNorm normalized name: Replesta NX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Navelbine IVD 25 mg/m2 D1、D8 Xeloda PO 1000 mg/m2 bid D1-D14 q21d
Trial: NCT03452891
Drug: Simvastatin-Methylcellulose
RxNorm normalized name: Methylcellulose
DrugBank: Methylcellulose (DB11228)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin-Methylcellulose gel will be placed in a deep (6-9 mm) periodontal pocket.
Trial: NCT03005665
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02446405
Drug: NSAA
RxNorm normalized name: Non-steroidal anti-inflammatory agent
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00741338
Drug: Azathioprine (Aza)
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Orally either every day for Cohort 1 or every other day for Cohort 2.
Trial: NCT02446405
Drug: LHRHA or Surgical Castration
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01059578
Drug: GSK206136
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK206136 2mg, 10mg, 50mg, 100mg capsule
Trial: NCT01059578
Drug: PLACEBO
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match 206136 2mg, 10mg, 50mg, 100mg capsule
Trial: NCT00582660
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg twice a day for 7 days prior to surgery
Trial: NCT00582660
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one tablet of placebo will be given for 7 days prior to surgery
Trial: NCT02255968
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules. All interventions are given as multiple doses
Trial: NCT02447601
Drug: PEX168
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200µg,injected subcutaneously,once a week.
Trial: NCT02447601
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40mg,oral,two times
Trial: NCT01181570
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 2 injections of placebo at week 0, one injection at week 1 and one injection every other week (EOW) thereafter.
Trial: NCT00659243
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One week treatment
Trial: NCT01554319
Drug: SB010
RxNorm normalized name: CATH,EXTERN SURESTEP START KIT #MECSB010
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three ascending dose groups are planned (Groups A, B, C), each consisting of 12 male subjects. Each of the 3 dose groups will be divided into 2 subgroups. First subgroup: 4 subjects (n=3 active compound, n=1 placebo); second subgroup: 8 subjects (n=6 active compound, n=2 placebo).~Each dose group will be investigated with a new group of 12 subjects (n=9 active compound, n=3 placebo). Dose escalation to next dose level will occur after satisfactory review of safety and tolerability and after review of the pharmacokinetic data (exposure control) of the preceding dose cohorts by the Safety Board.~Dose group A : 5 mg hgd40/2 mL; Dose group B: 10 mg hgd40/2 mL; Dose group C: 20 mg hgd40/2 mL.
Trial: NCT01554319
Drug: Placebo (phosphate-buffered saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three ascending dose groups are planned (Groups A, B, C), each consisting of 12 male subjects. Each of the 3 dose groups will be divided into 2 subgroups. First subgroup: 4 subjects (n=3 active compound, n=1 placebo); second subgroup: 8 subjects (n=6 active compound, n=2 placebo).~Each dose group will be investigated with a new group of 12 subjects (n=9 active compound, n=3 placebo). Dose escalation to next dose level will occur after satisfactory review of safety and tolerability and after review of the pharmacokinetic data (exposure control) of the preceding dose cohorts by the Safety Board.
Trial: NCT03277066
Drug: Diclofenac Sodium Active Topical Patch 1
RxNorm normalized name: diclofenac sodium Medicated Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HP-5000 Active Topical Patch 1 were applied on subjects with Osteoarthritis of the knee(s)
Trial: NCT03277066
Drug: Diclofenac Sodium Active Topical Patch 2
RxNorm normalized name: diclofenac sodium Medicated Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HP-5000 Active Topical Patch 2 were applied on subjects with Osteoarthritis of the knee(s)
Trial: NCT03277066
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical placebo patches were applied on subjects with Osteoarthritis of the knee(s)
Trial: NCT00778388
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study consists of a screening visit within 14 days before the administration of the investigational medicinal product (IMP), an experimental part of 180 days with seven outpatient visits on days 0, 3, 7, 14, 28, 90 and 180 and with vaccinations on days 0 and 7. IC43 vaccine will be administered intramuscularly during study visit 0 and 7 at three different doses, adjuvanted with Al(OH)3, or in one dose without Al(OH)3. Injection volumes will be 0.5 mL, 1 mL or 2 mL. Placebo will be administered intramuscularly at a dosage of 1 mL.
Trial: NCT01794247
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02253004
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00511732
Drug: Technosphere Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Technosphere Inhalation Powder
Trial: NCT00188266
Drug: cisplatinum combined with infusional fluorouracil (5 FU)
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Continuous 5FU via intravenous PICC line + 4 doses of Cisplatin every 2 weeks
Trial: NCT01513278
Drug: APN201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients receive APN201 and placebo at the same time. The irradiated region is divided vertically into two symmetric areas (left and right). One area is treated with APN201 (recombinant human superoxide dismutase (rhSOD) encapsulated in liposomal vesicles formulated as a hydrophilic gel; 1.6 mg rhSOD per mL), the other area is treated with placebo (empty liposomes formulated as a hydrophilic gel) in a double-blind fashion.~Study treatment (APN201 and placebo) starts on the day of initiation of radiation therapy and continues until the end of radiation therapy to the whole breast (25 or 28 daily fractions to a total dose of 50.0 Gy or 50.4 Gy, respectively). Study treatment is applied as a thin film on the irradiated area ≥10 minutes each day before radiation therapy (approximately 1 mL APN201 per 100 cm2 of the radiation field size and approximately 1 ml placebo per 100 cm2 of the radiation field size).
Trial: NCT01513278
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients receive APN201 and placebo at the same time. The irradiated region is divided vertically into two symmetric areas (left and right). One area is treated with APN201 (recombinant human superoxide dismutase (rhSOD) encapsulated in liposomal vesicles formulated as a hydrophilic gel; 1.6 mg rhSOD per mL), the other area is treated with placebo (empty liposomes formulated as a hydrophilic gel) in a double-blind fashion.~Study treatment (APN201 and placebo) starts on the day of initiation of radiation therapy and continues until the end of radiation therapy to the whole breast (25 or 28 daily fractions to a total dose of 50.0 Gy or 50.4 Gy, respectively). Study treatment is applied as a thin film on the irradiated area ≥10 minutes each day before radiation therapy (approximately 1 mL APN201 per 100 cm2 of the radiation field size and approximately 1 ml placebo per 100 cm2 of the radiation field size).
Trial: NCT01799837
Drug: [C-11]MENET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET imaging involves injecting small amounts of a radioactive material into the blood stream. The radioactive material is attached to a drug called MENET that will give information about how the brain interacts with a protein called norepinephrine (NE).
Trial: NCT00866944
Drug: FOLFOX 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX 4, every 14 days, 12 cycles
Trial: NCT02934464
Drug: FOLFOX 4
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02934464
Drug: mFOLFOX 6
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02934464
Drug: XELOX
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02914353
Drug: EP=7041
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Factor X!a Inhibitor
Trial: NCT02914353
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline
Trial: NCT01252277
Drug: Lovaza™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 capsules daily for 6 months
Trial: NCT00030472
Drug: pegylated liposomal doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02454855
Drug: melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral supplementation with melatonin (tablets) will be administered for 3 months once daily , 1-2 hours before bedtime. It will start on the day of the first administration of the new line of anticancer treatment (or no later on the day of the second administration of the new line of anticancer treatment).~Melatonin supplementation is achieved by the administration of (Circadin) at a dose of 2 mg / day according to its MA form of prolonged-release tablet of 2 mg.
Trial: NCT02454855
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral supplementation with placebo (tablets) will be administered for 3 months once daily , 1-2 hours before bedtime. It will start on the day of the first administration of the new line anticancer treatment (or no later on the day of the second administration of the new line of anticancer treatment).
Trial: NCT00098774
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mg/sq m IV infusion q 6 hrs starting 24 hrs after ea MTX dose until serum MTX \< or = 0.05uM Cycles 1-5.
Trial: NCT00098774
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 8 g/sq m IV infusion over 4 hrs Days 1 \& 15 Cycles 1, 2, \& 3; Day 15 Cycle 4 and Day 1 Cycle 5.
Trial: NCT00604682
Drug: CC10004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 X 10 mg caps taken once daily for a daily dose of 20 mg. Must be taken upon awakening and fasted
Trial: NCT00285103
Drug: SPC2996
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01478399
Drug: PB1023 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg Dose
Trial: NCT00780702
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive identical capsules containing no active medication plus standard methadone maintenance (daily oral methadone and weekly individual counseling).
Trial: NCT02006732
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00321178
Drug: SR4 - switch to CR4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: switch to oral treatment after 4 weeks SR 'standard' therapy
Trial: NCT00006123
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00690066
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of excipients of PROCHYMAL®
Trial: NCT00299130
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A stable dose of between 10-25 mg/week, oral or parenteral, as prescribed by the treating physician.
Trial: NCT00299130
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to rituximab intravenous infusion
Trial: NCT03732430
Drug: IBI308
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A humanized anti-PD-1 monoclonal antibody
Trial: NCT02171195
Drug: BIA 2-093
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIA 2-093 20mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 900 mg, 1200 mg
Trial: NCT02171195
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical placebo administered as oral tablets with 200 ml potable water.
Trial: NCT03405922
Drug: Placebo 40 mL Saline 0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of 40 mL 0.9% saline
Trial: NCT01897805
Drug: Heart-protecting Musk Pill
RxNorm normalized name: Tri-Heart Plus Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01897805
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02286258
Drug: Calcium EDTA
RxNorm normalized name: Calcium EDTA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium EDTA for equilibrium GFR measurement : bolus injection 30 mg/kg, then 10 mg/min perfusion for estimated renal clearance 100 mL /min for 4 hours.~Calcium EDTA for single injection GFR measurement : bolus injection depending on the estimated GFR
Trial: NCT02965417
Drug: Sym004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sym004 is a 1:1 mixture of two monoclonal antibodies (mAbs) which bind to two non-overlapping epitopes of the Epidermal Growth Factor Receptor (EGFR).
Trial: NCT02109653
Drug: LGX818
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral LGX818 300mg daily
Trial: NCT01555697
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each participant receives a single pill of placebo or active drug (memantine, 10 or 20 mg) and completes about 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.
Trial: NCT03198676
Drug: PrEP-001 6.4 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.4 mg as 4 sprays per nostril (ie total of 8 sprays for a single dose) using Aptar unit dose strength powder (UDSP) device
Trial: NCT03198676
Drug: PrEP-001 3.2 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.2 mg as 1 spray per nostril (ie total of 2 sprays for a single dose) using Aptar UDSP device
Trial: NCT01331993
Drug: Marketed enteric-coated naproxen formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marketed enteric-coated naproxen formulation (manufactured by Roche) 500 mg tablet
Trial: NCT04604795
Drug: GSK3915393 Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3915393 capsules will be given orally.
Trial: NCT04604795
Drug: GSK3915393 Solution for Infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3915393 solution for infusion will be administered intravenously.
Trial: NCT04604795
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching GSK3915393 capsules will be given orally.
Trial: NCT00384553
Drug: TEC
RxNorm normalized name: Ultec
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01434914
Drug: octenisept®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cutaneous solution
Trial: NCT01434914
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cutaneous use
Trial: NCT03278691
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15 mg (15 mg/ml) IV Q6H